Results 91 to 100 of about 51,036 (300)

Drugs and Cancer: an Analysis of the French Pharmacovigilance Database

open access: yes, 2013
Background. Our knowledge on cancers related to drugs remains limited. Among the different pharmacoepidemiological approaches assessing this risk, analysis of reports to pharmacovigilance (PV) system is uncommon. Objectives. To review
Jérémi Jégu   +11 more
core   +1 more source

Implementation and use of risk minimization control tools in the EU: A multistakeholder survey

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study characterized stakeholders' experiences with national implementation of risk minimization control tools (RMCTs), such as healthcare professional qualification, healthcare facility accreditation and medical intervention prior to treatment initiation, for eight medicinal products across eight European Union countries. Methods We conducted
Sharon C. M. Essink   +21 more
wiley   +1 more source

Improving the Pharmacovigilance System in Medical Organisations as an Opportunity to Enhance the Quality of Pharmacotherapy

open access: yesБезопасность и риск фармакотерапии
INTRODUCTION. It is essential to monitor the efficacy and safety of medicinal products as part of post-marketing surveillance to identify, assess, and prevent adverse drug reactions (ADRs).
M. V. Zhuravleva   +6 more
doaj   +1 more source

Application of real-time global media monitoring and ‘derived questions’ for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines

open access: yesBMC Medicine, 2017
Background The benefit-risk balance of vaccines is regularly debated by the public, but the utility of media monitoring for regulatory bodies is unclear.
Priya Bahri   +4 more
doaj   +1 more source

Pharmacovigilance in Asia

open access: yesJournal of Pharmacology and Pharmacotherapeutics, 2013
An increase in drug safety concerns in recent years with some high profile drug withdrawals have led to raising the bar by various stakeholders more importantly by the regulatory authorities. The number of Adverse Drug Reactions (ADRs) reported have also resulted in an increase in the volume of data handled and to understand pharmacovigilance a high ...
openaire   +3 more sources

Pharmacovigilance at SKIMS Srinagar (J&K) -

open access: yes, 2005
Pharmacovigilance is an emerging discipline that encompases several vital issues concerning safe and rational use of drugs and pharmaceuticals. In view of the huge annual inflow of patients running into lakhs in number, use of large quantities of ...
Tanki, Shafiqa Aslam   +3 more
core  

DEBATABLE PROBLEMS OF PHARMACOVIGILANCE [PDF]

open access: yes, 2018
The paper discusses the possible causes of the problems related to ...
L. A. Muravyevа, Yu. V. Muravyev
core   +1 more source

Paediatric clonidine medication errors: Findings from a multicentre French study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to describe the characteristics of medication errors involving clonidine in paediatric patients and reported to French Network of Pharmacovigilance and Poison Control Centres. Methods This retrospective observational study analysed clonidine‐related medication errors reported between 1985 and June 2024 in patients under 12 years ...
Eve‐Marie Thillard   +8 more
wiley   +1 more source

PHARMACOVIGILANCE: A REVIEW ARTICLE [PDF]

open access: yes, 2016
Pharmacovigilance (Pv) is an important tool for the safety and ensuring that the patients are safe in every aspect of the drugs being taken in any form.
SHILPI, KAJAL   +2 more
core   +1 more source

Cefepime exposure in prolonged or intermittent infusion in critically ill children

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Cefepime is commonly used in critically ill children for whom there is a high between‐subject variability. To reach the therapeutic pharmacokinetic (PK) target in critically ill patients, prolonged infusion of beta‐lactams seems to be the most efficient.
Marc Hobeika   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy